Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Marth

Showing results (41-50 of 237) with videos related to

Pageof 24
Sort By:
Archives of Gynecology and Obstetrics|June 14, 2021
Efficacy of an optimal ovarian cancer screening: a best-case scenario study based on real-world dataLena Steinkasserer, Delmarko Irmgard, Tatjana Weiss, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|February 22, 2017
L1CAM and HER2 Expression in Early Endometrioid Uterine CancerSamira Abdel Azim, Susanne Sprung, Irene Mutz-Dehbalaie, et al.
Anticancer Research|October 15, 2010
Importance of erythropoetin receptor expression in tumour tissue for the clinical course of breast cancerBirgit Volgger, Katharina Kurz, Kathrin Zöschg, et al.
Cancer Biology & Therapy|May 25, 2006
Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-gamma and EGFDaniel Reimer, Susann Sadr, Annemarie Wiedemair, et al.
Gynecologic Oncology|March 23, 2007
Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximabChristian Marth, Daniel Egle, Doris Auer, et al.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2025
Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancerKatharina Steger, Heidelinde Fiegl, Barin Feroz, et al.
Gynecologic Oncology|April 25, 2012
HE4 is an independent prognostic marker in endometrial cancer patientsIrene Mutz-Dehbalaie, Daniel Egle, Siegfried Fessler, et al.
Breast (Edinburgh, Scotland)|December 6, 2007
Disseminated tumor cells: are they ready for clinical use?Stephan Braun, Florian D Vogl, Alois Schneitter, et al.
Gynecologic Oncology Reports|March 5, 2026
Highlighting the molecular refinement of NSMP endometrial cancer in a case of mesonephric-like adenocarcinomaKatharina Steger, Simon Schnaiter, Sigurd Lax, et al.
Gynecologic Oncology|February 9, 2023
An angiogenic tumor phenotype predicts poor prognosis in ovarian cancerVerena Wieser, Irina Tsibulak, Daniel Uwe Reimer, et al.
Pageof 24

Showing results (41-50 of 237) with videos related to

Sort By:
Pageof 24
Archives of Gynecology and Obstetrics|June 14, 2021
Efficacy of an optimal ovarian cancer screening: a best-case scenario study based on real-world dataLena Steinkasserer, Delmarko Irmgard, Tatjana Weiss, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|February 22, 2017
L1CAM and HER2 Expression in Early Endometrioid Uterine CancerSamira Abdel Azim, Susanne Sprung, Irene Mutz-Dehbalaie, et al.
Anticancer Research|October 15, 2010
Importance of erythropoetin receptor expression in tumour tissue for the clinical course of breast cancerBirgit Volgger, Katharina Kurz, Kathrin Zöschg, et al.
Cancer Biology & Therapy|May 25, 2006
Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-gamma and EGFDaniel Reimer, Susann Sadr, Annemarie Wiedemair, et al.
Gynecologic Oncology|March 23, 2007
Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximabChristian Marth, Daniel Egle, Doris Auer, et al.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2025
Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancerKatharina Steger, Heidelinde Fiegl, Barin Feroz, et al.
Gynecologic Oncology|April 25, 2012
HE4 is an independent prognostic marker in endometrial cancer patientsIrene Mutz-Dehbalaie, Daniel Egle, Siegfried Fessler, et al.
Breast (Edinburgh, Scotland)|December 6, 2007
Disseminated tumor cells: are they ready for clinical use?Stephan Braun, Florian D Vogl, Alois Schneitter, et al.
Gynecologic Oncology Reports|March 5, 2026
Highlighting the molecular refinement of NSMP endometrial cancer in a case of mesonephric-like adenocarcinomaKatharina Steger, Simon Schnaiter, Sigurd Lax, et al.
Gynecologic Oncology|February 9, 2023
An angiogenic tumor phenotype predicts poor prognosis in ovarian cancerVerena Wieser, Irina Tsibulak, Daniel Uwe Reimer, et al.
Pageof 24